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Aims Atrial fibrillation (AF) is commonly associated with a high risk of stroke, thromboembolism, and mortality. The 1-year
follow-up of the EURObservational Research Programme-Atrial Fibrillation (EORP-AF) Pilot Registry demonstrated a
high mortality but good outcomes with European Society of Cardiology guideline-adherent therapy. Whether these
‘real-world’ observations on patients managed by European cardiologists extend to 2 years remains uncertain.
Methods
and results
In this report from the EORP-AFGeneral Registry Pilot Phase, we provide data on the 2-year follow-up outcomes. Con-
sistent with the 1-year follow-up report, only a small proportion of patients were symptomatic (24.9%), with minor
differences between the different AF subtypes. Persistence of oral anticoagulant (OAC) therapy remains high at 2-years,
with 80% of patients treated with OAC. The prescribing rates of non-vitamin K antagonist oral anticoagulants are
progressively increasing (13.7% at 2 years). Rate and rhythm control approaches remained consistent across the entire
follow-up observation. Overall mortality rates remained high, with 5.0% of patients dead during the 2-year follow-up,
mostly due to cardiovascular causes (61.8%). Atrial fibrillation readmissions were frequent, particularly related to
arrhythmias and heart failure. On multivariate analyses, any cardiovascular reason for admission rather than AF was
significantly associated with increased mortality during the 2-year follow-up.
Conclusion In this 2-year follow-up report from EORP-AF, mortality rates with AF remain high from cardiovascular causes, despite
the high prevalent use of OAC. Improved management strategies to reduce major adverse outcomes in AF patients are
needed.
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Introduction
Atrial fibrillation (AF) represents one of the most common arrhyth-
mias reported in adult patients.1 With the progressive ageing popu-
lation, both AF prevalence and incidence have been progressively
increasing, according to older age and male sex.1 In Europe, the
current AF prevalence in subjects older than 55 years has been es-
timated to be 8.8million in 2010 and projected to rise to 17.9 million
in 2050.1
Atrial fibrillation confers a high-risk for both cardiovascular and
non-cardiovascular complications, particularly with a five-fold higher
risk of stroke and thromboembolism compared with non-AF
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population.1,2 Considering the huge clinical impact and healthcare
burden associated with AF, the collection of prospective data from
‘real-world’ AF cohorts could help establish best practice and explore
options in reducing both morbidity and mortality. Importantly, the
introduction of the non-vitamin K oral anticoagulants (NOACs)3
have led to a major change in the landscape of stroke prevention in
AF. Indeed, recent data from the GLORIA-AF Phase II study show
how the percentage of patients treated with NOACs is increasing
worldwide.4 Nonetheless, the proportion of high-risk patients being
untreated or treated with antiplatelet (AP) drugs is higher than ex-
pected, as reported in the 1-year follow-up from the EURObserva-
tional Research Programme-Atrial Fibrillation (EORP-AF) General
Registry Pilot Phase.5 The 1-year follow-up of the EORP-AF Pilot
Registry also demonstrated good outcomes with European Society
of Cardiology (ESC) guideline-adherent therapy.6
Whether these ‘real-world’ observations on patients managed by
European cardiologists extend to 2 years remains uncertain. In this
report from the EORP-AF General Registry Pilot Phase, we provide
data on the 2-year follow-up outcomes.
Methods
The EORP-AF General Registry is a prospective, observational, multi-
centre European-wide registry about AF patients in current cardiology
practice held by ESC. Details about study protocol, design, and main
results have been published elsewhere.5–7
Briefly, EORP-AF Pilot Phase enrolled consecutive AF patients
managed by cardiologists in nine ESC members European countries
(Belgium, Denmark, Netherlands, Norway, Poland, Romania, Greece,
Italy, and Portugal). The study enrolled both in- and outpatients acces-
sing to cardiology services (either hospital or office-based centres) with
AF as a primary or secondary diagnosis. The qualifying AF event
was recorded by a 12-lead ECG, 24 h ECG Holter, or other electro-
cardiographic documentation and should have been occurred within
the 12 months before the enrolment.
Follow-up was performed by the local cardiologist investigator every
1 year after enrolment, for a total of 3-year planned follow-up time. End-
points of interest were mortality, stroke/thromboembolism, cardiovas-
cular co-morbidities, and hospital readmissions. Data about first-year
follow-up analysis was recently published.5 For the purposes of the pre-
sent paper, we focus on the outcomes recorded during the second-year
follow-up.
Based on the ESC guidelines,2 thromboembolic risk was defined ac-
cording to the CHA2DS2-VASc score.
1 ‘Low-risk’ patients were defined
as males with a CHA2DS2-VASc 0 or females with a CHA2DS2-VASc
equal to 1; ‘moderate risk’ was defined as male patients with a CHA2
DS2-VASc score 1; and ‘high risk’ was defined as CHA2DS2-VASc score
≥2.1 Moreover, bleeding risk was assessed based on the HAS-BLED
bleeding score.1
Statistical analysis
Univariate analysis was applied to both continuous and categorical vari-
ables. Continuous variables were reported as mean+ SD and/or as me-
dian and inter-quartile range (IQR). Among-group comparisons were
made using a non-parametric test (Kruskal–Wallis test). Categorical
What’s new?
† In the 2-year follow-up of EURObservational Research Pro-
gramme on Atrial Fibrillation General Registry Pilot Phase,
there was a high rate of adverse events, particularly all-cause
mortality, despite a high prevalence of oral anticoagulant use.
† The high mortality risk was associated with major cardiovas-
cular co-morbidities other than atrial fibrillation (AF).
† Greater efforts are needed to ensure optimal medical man-
agement of associated co-morbidities in AF patients to im-
prove mortality rates.
Enrolled Patients
n = 3119
Patients died during
main part
n = 10
*1 Patient with type of AF unknown
**52 Patient with type of AF unknown
Patients alive
at main part
n = 3109
Patients lost to
1 year follow up
n = 467
Patients died during
1 year follow up
n = 167*
Patients at least one
visit/contact during
1 year follow up
n = 2475**
Patients withdrow of
consent at
2 years follow up
n = 3
Patients still lost to
2 years follow up
n = 407
Patients died during
2 years follow up
n = 13
Patients died during
2 years follow up
n = 101
Patients at least one
visit/contact during
2 years follow up
n = 44
Patients at least one
visit/contact during
2 years follow up
n = 1845
Patients at least one visit/
contact during
2 years follow up
n = 1889
Patients lost to
2 years follow up
n = 542
Patients lost to
2 years follow up
n = 952
Patients died during
2 years follow up
n = 88
Figure 1 Patient flow as part of the EORP-AF Pilot General Registry.
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Table 1 Demographic and baseline characteristics according to atrial fibrillation subtype
Total First detected Paroxysmal Persistent Long-standing
persistent AF
Permanent P-value
Age (years) (mean+ SD) 68.6+11.2
(n ¼ 1953)
68.5+12.2
(n ¼ 552)
66.6+10.9
(n ¼ 525)
67.4+10.6
(n ¼ 430)
69.9+10.2
(n ¼ 100)
72.9+9.9
(n ¼ 346)
,0.0001*
Age (years) (median [IQR]) 69.0 [62.0–77.0]
(n ¼ 1953)
70.0 [62.0–77.0]
(n ¼ 552)
67.0 [60.0–74.0]
(n ¼ 525)
68.0 [61.0–75.0]
(n ¼ 430)
69.0 [63.0–78.5]
(n ¼ 100)
74.0 [66.0–80.0]
(n ¼ 346)
Age (years, %) ,0.0001**
≤65 36.3 (708/1953) 34.4 (190/552) 43.0 (226/525) 41.9 (180/430) 32.0 (32/100) 23.1 (80/346)
.65 63.7 (1245/1953) 65.6 (363/552) 57.0 (299/525) 58.1 (250/430) 68.0 (68/100) 76.9 (80/346)
Gender (%) 0.2098**
Male 60.6 (1183/1953) 63.9 (353/552) 57.9 (304/525) 61.9 (266/430) 61.0 (61/100) 57.5 (199/346)
Female 39.4 (770/1953) 36.1 (199/552) 42.1 (221/525) 38.1 (164/430) 39.0 (39/100) 42.5 (147/346)
CHA2DS2-VASc (%) ,0.0001**
Low risk 8.1 (159/1953) 7.8 (43/552) 13.0 (68/525) 7.2 (31/430) 4.0 (4/100) 3.8 (13/346)
Moderate risk 11.2 (218/1953) 11.2 (218/1953) 11.2 (218/1953) 11.2 (218/1953) 11.2 (218/1953) 11.2 (218/1953)
High risk 80.7 (1576/1953) 80.1 (442/552) 73.1 (384/525) 79.8 (343/430) 88.0 (88/100) 92.2 (319/346)
HAS-BLED score class (%) 0.0007**
0–2 86.5 (1690/1953) 86.2 (476/552) 90.7 (476/525) 87.4 (376/430) 80.0 (80/100) 81.5 (282/346)
≥3 13.5 (263/1953) 13.8 (76/552) 9.3 (49/525) 12.6 (54/430) 20.0 (20/100) 18.5 (64/346)
Follow-up duration (days) (mean+ SD) 742.3+74.0
(n ¼ 1855)
737.5+68.9
(n ¼ 511)
742.9+77.8
(n ¼ 514)
742.6+72.8
(n ¼ 411)
750.7+91.8
(n ¼ 99)
745.9+71.2
(n ¼ 320)
0.0046*
Follow-up duration (days) (median [IQR]) 735 [721–760]
(n ¼ 1855)
738 [719–760]
(n ¼ 511)
733 [720–757]
(n ¼ 514)
737 [726–760]
(n ¼ 411)
730 [721–735]
(n ¼ 99)
742 [723–761]
(n ¼ 320)
Current symptoms at 2-year follow-up (%) 24.9 (462/1855) 18.4 (94/511) 23.9 (123/514) 28.5 (117/411) 27.3 (27/99) 31.6 (101/320) 0.0002**
Palpitations (%) 65.6 (303/462) 63.8 (60/94) 82.1 (101/123) 65.0 (76/117) 63.0 (17/27) 48.5 (49/101) ,0.0001**
Dizziness (%) 10.8 (50/462) 10.6 (10/94) 10.6 (13/123) 11.1 (13/117) 11.1 (3/27) 10.9 (11/101) 0.9999**
General non-wellbeing (%) 28.8 (133/462) 26.6 (25/94) 29.3 (36/123) 27.4 (32/117) 51.9 (14/27) 25.7 (26/101) 0.0986**
Fatigue (%) 44.6 (206/462) 40.4 (38/94) 32.5 (40/123) 46.2 (54/117) 63.0 (17/27) 56.4 (57/101) 0.0016**
Shortness of breath (%) 41.3 (191/462) 42.6 (40/94) 39.0 (48/123) 31.6 (37/117) 55.6 (15/27) 50.5 (51/101) 0.0311**
Chest pain (%) 11.3 (52/462) 14.9 (14/94) 13.8 (17/123) 9.4 (11/117) 7.4 (2/27) 7.9 (8/101) 0.4083**
Fear/anxiety (%) 8.2 (38/462) 7.4 (7/94) 8.1 (10/123) 6.8 (8/117) 18.5 (5/27) 7.9 (8/101) 0.3825**
Other (%) 1.5 (7/462) 0.0 (0/94) 0.8 (1/123) 5.1 (6/117) 0.0 (0/27) 0.0 (0/101) 0.0142**
*P-values for among-group comparisons are from Fisher’s exact test.
**P-values for among-group comparisons are from Kruskall–Wallis test.
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variables were reported as percentages. Among-group comparisons
were made using a x2 test or Fisher’s exact test if any expected cell
count was ,5. Plots of the Kaplan–Meier curves for time to all-cause
death in relation to AF subtype were performed. The survival distribu-
tions between the types of AF have been compared using the log-rank
test. All the variables at entry that were statistically significant at univari-
ate analysis and variables considered of relevant clinical interest were
included in the multivariable model (logistic regression) to identify the
independent predictors of the composite outcome of stroke/transient
ischaemic attack (TIA)/peripheral embolism and/or death during the
second-year follow-up period. Cox regression analysis was performed
to establish clinical factors independently associated with death occur-
rence. A two-sided P-value of ,0.05 was considered as statistically
significant. All analyses were performed using the SAS statistical soft-
ware version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
The original study cohort comprised 3109 AF patients enrolled
from 2012 to 2013. During the first-year follow-up, 167 (5.4%) pa-
tients died, while 467 (15.0%) patients were lost to follow-up. Clin-
ical status during the second-year follow-up was available for 1990
(64.0%) patients (Figure 1). Of these, 101 (5.1%) died and 1889 had
at least one visit/contact during the second-year follow-up.
VKA
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
NOAC AP alone
ATT at baseline
OAC + AP Other
2.0
3.8
4.6
9.3
80.3
2.1
1.5
5.0
88.8
8.7
87.5
1.1
2.7 3.4
5.4
76.6
5.9
8.8
27.4
60.9
2.3
12.5
12.5
12.5
12.5
50.0
3.6
5.9
2.7
1.5
5.3
20.7
29.2
17.7
27.2
40.0
7.2
5.6
45.1
2.1 7.9
13.2
7.9
15.8
55.3
1.5
82.4
14.7
ATT at 2 year
Other
OAC + AP
AP Alone
NOAC
VKA
ATT at 2 year
Other
OAC + AP
AP Alone
NOAC
VKA
VKA
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
NOAC AP alone
ATT at 1 year before consultation
OAC + AP Other
Figure 2 Antithrombotic therapy at 2-year follow-up according to baseline and 1-year. AP, antiplatelet; ATT, antithrombotic therapy;
OAC, oral anticoagulant; NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist.
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Table 2 Pharmacological treatments prescribed at follow-up
Total First detected Paroxysmal Persistent Long-standing
persistent AF
Permanent P-value
(A) Antithrombotic drugs by AF subgroup
Oral anticoagulant (at least one) (%)
Before consultation 79.5 (1475/1855) 69.5 (355/511) 79.0 (406/514) 85.9 (353/411) 79.8 (79/99) 88.1 (282/320) ,0.0001
After consultation 79.2 (1469/1855) 71.0 (363/511) 77.6 (399/514) 84.2 (346/411) 79.8 (79/99 88.1 (282/320) ,0.0001
VKA (at least one) (%)
Before consultation 65.0 (1205/1855) 55.2 (282/511) 62.3 (320/514) 69.3 (285/411) 71.7 (71/99) 77.2 (247/320) ,0.0001
After consultation 64.2 (1190/1855) 56.8 (290/511) 60.1 (309/514) 67.4 (277/411) 71.7 (71/99) 75.9 (243/320) ,0.0001
NOAC (at least one) (%)
Before consultation 13.3 (246/1855) 12.9 (66/511) 15.2 (78/514) 14.4 (59/411) 8.1 (8/99) 10.9 (35/320) 0.2045
After consultation 13.7 (255/1855) 13.1 (67/511) 15.8 (81/514) 14.6 (60/411) 8.1 (8/99) 12.2 (39/320) 0.2382
Antiplatelet drug (at least one) (%)
Before consultation 25.1 (466/1855) 25.6 (131/511) 23.0 (118/514) 25.8 (106/411) 39.4 (39/99) 22.5 (72/320) 0.0097
After consultation 23.8 (441/1855) 23.9 (122/511) 23.2 (119/514) 22.9 (94/411) 36.4 (36/99) 21.9 (70/320) 0.0479
Total Low risk Moderate risk High risk P-value
(B) Antithrombotic drugs by thromboembolic risk
Oral anticoagulant (at least one) (%)
Before consultation 79.7 (1505/1889) 44.7 (71/159) 74.3 (165/222) 84.2 (1269/1508) ,0.0001
After consultation 79.3 (1498/1889) 43.4 (69/159) 73.9 (164/222) 83.9 (1265/1508) ,0.0001
VKA (at least one) (%)
Before consultation 65.1 (1230/1889) 32.7 (52/159) 52.7 (117/222) 70.4 (1061/1508) ,0.0001
After consultation 64.2 (1213/1889) 31.4 (50/159) 52.3 (116/222) 69.4 (1047/1508) ,0.0001
NOAC (at least one) (%)
Before consultation 13.2 (250/1889) 10.7 (17/159) 19.4 (43/222) 12.6 (190/1508) 0.0129
After consultation 13.8 (260/1889) 11.3 (18/159) 19.4 (43/222) 13.2 (199/1508) 0.0289
Antiplatelet drug (at least one) (%)
Before consultation 25.0 (473/1889) 17.6 (28/159) 17.1 (38/222) 27.0 (407/1508) 0.0005
After consultation 23.7 (447/1889) 16.4 (26/159) 18.0 (40/222) 25.3 (381/1508) 0.0046
Continued
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Demographic and baseline characteristics according to AF sub-
type were reported in Table 1, with 37 (1.9%) patients being ex-
cluded because no data about AF subtype were available. Mean
follow-up duration for the entire cohort was 742.3 days+ SD
74.0 (median 735 [IQR: 721–760] days).
Similar to the 1-year follow-up analysis,5 permanent AF patients
were older than those in other AF clinical subtypes (P, 0.0001).
No difference was found in gender distribution across AF subtypes
(P ¼ 0.2098). High-stroke-risk patients were more prevalent in pa-
tients with long-standing persistent and permanent AF (P, 0.0001),
as was high bleeding risk, according to HAS-BLED score (P ¼ 0.0007).
Symptomatic status at 2-year follow-up
At 2-year follow-up, one-quarter of patients were symptomatic
(n ¼ 462, 24.9% of patients). The presence of symptoms progres-
sively increased across the AF subtypes, being more prevalent in pa-
tients with permanent AF (P ¼ 0.0002). Of the various symptoms,
palpitations were more frequently reported in paroxysmal
AF (P, 0.0001), while fatigue and shortness of breath were
more prevalent with long-standing persistent and permanent AF
(P ¼ 0.0016 and 0.0311, respectively).
Antithrombotic therapy at 2-year
follow-up
Antithrombotic therapy use at the 2-year follow-up according to
baseline and 1-year follow-up are reported in Figure 2. Similar to
previously reported data, most of the patients who were treated
with vitamin K antagonist (VKA) and NOACs at the baseline and
at 1-year follow-up were still treated with the same oral anticoagu-
lants (OACs) (i.e. 80.3 and 82.4%, respectively). A relatively large
proportion of patients treated with AP at baseline were changed
to VKA (27.2%) or to a NOAC (17.7%), or prescribed with AP +
OAC (20.7%).
As reported in Table 2, the overall proportion of patients treated
with OAC remained consistently high, both before and after con-
sultation (79.5 and 79.2%, respectively). Patients with permanent
AF were more frequently treated with OAC than patients in other
AF subtypes (P, 0.0001), with same proportion before and after
the consultation (88.1%). The proportion of patients treated with
VKA progressively increased from patients with first detected AF
to permanent AF, both before and after consultation (P,
0.0001). Patients with long-standing persistent AF were more fre-
quently treated with AP before consultation (P ¼ 0.0097), with
the proportion reduced after consultation (P ¼ 0.0479).
When considered thromboembolic risk (Table 2), patients at high
thromboembolic riskweremore frequently treatedwithOAC (79%),
compared with AP drugs (P, 0.0001). Prescription of VKA progres-
sively increased from low to high thromboembolic risk, both before
and after consultation (P, 0.0001), while NOACs were significantly
more prescribed in AF patients at moderate risk (P ¼ 0.0129 and
0.0289, respectively, before and after consultation). Antiplatelet was
more frequently used in patients at high thromboembolic risk.
Clinical management at 2-year follow-up
The use of rhythm and rate control drugs is summarized in Table 2.
b-Blockers were still the most commonly used drugs, but no
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differences were found between the different AF subtypes (P ¼
0.7403). Digoxin was still used in almost the half of the patients,
being more frequently prescribed in patients with long-standing per-
sistent AF and permanent AF (P, 0.0001). As expected, both Class
Ic and Class III antiarrhythmics were more frequently prescribed to
patients with paroxysmal and persistent AF (both P, 0.0001).
A high proportion of patients assigned to rate control at baseline
were continued on that approach, consistently throughout the ob-
servation period (Figure 3). Interventional procedures were used in a
minority of patients (n ¼ 260, 14.2%), with electrical cardioversion
being the most performed (n ¼ 107, 5.8%). Both pharmacological
and electrical cardioversion, as well as catheter ablation, were
more likely used in patients with paroxysmal AF (10.1, 8.9, and
5.1% respectively; all P, 0.0001).
Mortality and morbidity
A total of 98 patients from the 1953 (5.0%) whose follow-up status
was known died during the 2-year follow-up (Table 3). Similar to
what was reported for the 1-year follow-up, the highest death rates
were reported for patients with both first detected (7.4% of
patients) and permanent AF (7.5%) subtypes (P, 0.0001).
The highest proportion of patients died owing to cardiac cause
(52.6%), particularly from heart failure (77.5%). Kaplan–Meier
curves (Figure 4) for death according to AF subtypes found a sig-
nificant difference in death risk between the AF subtypes, with
the highest risk among patients with first detected AF or per-
manent AF, and lowest risk among patients with paroxysmal AF
(P, 0.0001).
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Figure 3 Clinical management at 2-year follow-up according to baseline and 1-year.
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Patients with paroxysmal AF weremore frequently readmitted to
hospital (P, 0.0001) due to AF, atrial flutter, or atrial tachycardia
(Table 3). Patients with permanent AF were more frequently re-
admitted to the hospital for other cardiovascular events (P,
0.0001). Readmissions related to chronic heart failure (CHF) occur-
rencewere themost common (42.4%) but with no difference across
AF subtypes.
Multivariate analyses
A logistic regression analysis to establish clinical factors associated
with the composite outcome of stroke/TIA/peripheral embolism
and/or death occurrence was compiled (Table 4). Of the clinical
characteristics, age (P, 0.0001), other main reason for admission
(P, 0.0001), first detected AF (P ¼ 0.0083), no physical activity
(P ¼ 0.0001), CHF (P, 0.0001), chronic kidney disease (P,
0.0001), diabetes (P ¼ 0.0018), malignancy (P ¼ 0.0208), calcium-
channel blockers (P ¼ 0.0013), and angiotensin-converting enzyme
(ACE) inhibitors (P ¼ 0.0031) were independently associated with
the occurrence of the composite outcome (Figure 5A).
Cox regression analysis (Table 5) shows that age (P, 0.0001), other
main reason for admission (P, 0.0001), first detected AF (P ¼
0.0005), no physical activity (P ¼ 0.0001), CHF (P, 0.0001), chronic
kidney disease (P, 0.0001), diabetes (P ¼ 0.0003), malignancy (P ¼
0.0430), and heparin use (P ¼ 0.0327) were independently associated
with death (Figure 5B); conversely, statins (P ¼ 0.0053), calcium-
channel blockers (P ¼ 0.0050), and ACE inhibitors (P ¼ 0.0032)
were protective against death during the 2-year follow-up (Figure 5B).
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3 Mortality and morbidity by 2-year follow-up
Total First detected Paroxysmal Persistent Long-standing
persistent AF
Permanent P-value
(A) Mortality
Death (%) 5.0 (98/1953) 7.4 (41/552) 2.1 (11/525) 4.4 (19/430) 1.0 (1/100) 7.5 (26/346) ,0.0001
Causes of death (details) (%) 0.1336
Cardiac 52.6 (40/76) 36.4 (12/33) 50.0 (4/8) 64.7 (11/17) – 72.2 (13/18)
Vascular 9.2 (7/76) 18.2 (6/33) 0.0 (0/8) 5.9 (1/17) – 0.0 (0/18)
Non-cardiovascular 38.2 (29/76) 45.5 (15/33) 50.0 (4/8) 29.4 (5/17) – 27.8 (5/18)
Cardiac (%) 0.1109
Acute myocardial infarction 5.0 (2/40) 8.3 (1/12) 0.0 (0/4) 0.0 (0/11) – 7.7 (1/13)
Heart failure 77.5 (31/40) 83.3 (10/12) 75.0 (3/4) 54.5 (6/11) – 92.3 (12/13)
Arrhythmia 7.5 (3/40) 0.0 (0/12) 25.0 (1/4) 18.2 (2/11) – 0.0 (0/13)
Other 10.0 (4/40) 8.3 (1/12) 0.0 (0/4) 27.3 (3/11) – 0.0 (0/13)
Vascular (%) 0.9999
Ischaemic stroke 42.9 (3/7) 33.3 (2/6) – 100.0 (1/1) – –
Haemorrhagic stroke 14.3 (1/7) 16.7 (1/6) – 0.0 (0/1) – –
Systemic haemorrhage 42.9 (3/7) 50.0 (3/6) – 0.0 (0/1) – –
(B) Readmissions
AF/atrial flutter/atrial tachycardia (%) 12.0 (209/1743) 9.7 (48/494) 20.8 (103/495) 11.6 (42/363) 9.8 (8/82) 2.6 (8/309) ,0.0001
Other cardiovascular events (%) 8.2 (145/1778) 9.7 (48/496) 5.0 (25/500) 5.0 (19/383) 5.7 (5/87) 15.4 (48/312) ,0.0001
ACS 4.2 (6/143) 6.4 (3/47) 8.3 (2/24) 5.3 (1/19) 0.0 (0/5) 0.0 (0/48) 0.2486
Heart failure 42.4 (61/144) 46.8 (22/47) 24.0 (6/25) 31.6 (6/19) 20.0 (1/5) 54.2 (26/48) 0.0749
MI/angina 13.3 (19/143) 12.8 (6/47) 16.7 (4/24) 10.5 (2/19) 40.0 (2/5) 10.4 (5/48) 0.4116
Arrhythmia, other than
AF/atrial flutter
9.8 (14/143) 8.5 (4/47) 20.8 (5/24) 5.3 (1/19) 0.0 (0/5) 8.3 (4/48) 0.4703
Cardiac arrest 0.7 (1/143) 2.1 (1/47) 0.0 (0/24) 0.0 (0/19) 0.0 (0/5) 0.0 (0/48) 0.6723
Stroke 6.3 (9/143) 6.4 (3/47) 4.2 (1/24) 0.0 (0/19) 0.0 (0/5) 10.4 (5/48) 0.6872
TIA 2.8 (4/143) 2.1 (1/47) 8.3 (2/24) 0.0 (0/19) 0.0 (0/5) 2.1 (1/48) 0.5024
Peripheral embolism 2.1 (3/143) 2.1 (1/47) 0.0 (0/24) 5.3 (1/19) 20.0 (1/5) 0.0 (0/48) 0.0378
Pulmonary embolism 0.7 (1/143) 0.0 (0/47) 0.0 (0/24) 5.3 (1/19) 0.0 (0/5) 0.0 (0/48) 0.1685
Other cardiovascular events 16.8 (24/143) 8.5 (4/47) 20.8 (5/24) 31.6 (6/19) 0.0 (0/5) 18.8 (9/48) 0.1600
Non-cardiovascular events (%) 9.7 (156/1604) 12.3 (55/447) 9.1 (42/464) 8.9 (31/348) 8.2 (6/73) 8.1 (22/272) 0.2967
Bleeding 11.0 (16/145) 11.8 (6/51) 11.9 (5/42) 3.7 (1/27) 0.0 (0/5) 20.0 (4/20) 0.4924
Other non-cardiovascular events 90.2 (138/153) 94.4 (51/54) 85.4 (35/41) 96.8 (30/31) 83.3 (5/6) 81.0 (17/21) 0.1274
P-values for among-group comparisons are from Pearson’s x2 test.
AF, atrial fibrillation; MI, myocardial infarction; TIA, transient ischaemic attack.
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Discussion
During the 2-year follow-up of the EORP-AF Pilot General Registry,
our data are consistent with those previously reported for the
1-year follow-up analysis.5 The vast majority of AF patients persist
to remain asymptomatic, while those still experiencing symptoms
had differential patterns according to different AF subtype. Persist-
ence with OAC use was still high (79.5%), with the use of NOACs
increasing.
Rate control was the most common approach used in the overall
population, with even lower rates of both pharmacological and elec-
trical cardioversion procedures, as well as for catheter ablation.
Mortality rates were consistently high (5.0%), with more than a
half due to cardiac or vascular causes. Hospital readmissions were
common, even if slightly reduced compared with that reported
for the 1-year follow-up. Different to that reported during the
1-year follow-up, any other cardiovascular reason for admission
than AF was independently directly associated with increased
mortality.
Asymptomatic AF was still common, being reported up to 40% of
patients.8 Of importance, being asymptomatic was not associated
with a lower thromboembolic risk8 and is frequently associated
with stroke occurrence.9 The ESC guidelines still recommend
opportunistic screening for AF in all patients aged 65 or more,2
but increasing evidence suggests that we should reconsider much
wider systematic screening.9 Indeed, even a single screening point
could identify many new AF patients,10 especially with more recent
approaches using new technology devices that are both feasible and
cost-effective in identifying new ‘high-risk’ AF patients.11
Our data show how the persistence of OAC therapy use is still
high, even after 2 years of follow-up, with almost 80% of patients still
being treated and almost 85% of these being at high thromboembol-
ic risk. Even if prior data about OAC use showed lower figures, our
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 4 Logistic regression analysis for predictors of
stroke/TIA/peripheral embolism and/or mortality by
2-year follow-up
Odds
ratio
95% confidence
interval
P-value
Age (per year) 1.06 1.04–1.08 ,0.0001
Other main reason for
admission vs. AF
1.92 1.39–2.66 ,0.0001
First detected AF vs.
permanent AF
1.67 1.14–2.45 0.0083
None vs. regular physical
activity
2.71 1.63–4.51 0.0001
Chronic heart failure 2.18 1.57–3.04 ,0.0001
Chronic kidney disease 2.35 1.67–3.31 ,0.0001
Diabetes 1.67 1.21–2.30 0.0018
Malignancy 1.85 1.10–3.11 0.0208
Calcium-channel
blockers
0.41 0.24–0.71 0.0013
ACE inhibitors 0.63 0.47–0.86 0.0031
ACE, angiotensin-converting enzyme; AF, atrial fibrillation; TIA, transient ischaemic
attack.
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Figure 4 Kaplan–Meier curves for death according to atrial fibrillation subtypes. FU, follow-up; LS, long-standing.
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data seem to confirm other reports from different AF cohorts. In-
deed, the GLORIA-AF Phase II study reported that 80% of patients
from Europe were treated with at least one OAC drug.4 In this
2-year follow-up report, we describe an increasing use for NOACs,
but more than a half of the patients were still treated with VKA. This
is in contrast to data from GLORIA-AF, which reported that 47.7%
of patients were prescribed with NOACs.4 This difference could be
easily explained by the fact that our patients were enrolled during
the early period following the introduction of NOACs, and many
patients well managed with VKA would not be automatically chan-
ged to NOACs.12 Also, many countries participating in the
EORP-AF Pilot Registry have some limitations on NOAC usage
due to costs. Of note, reassuring real-world efficacy and safety
data onNOACs are progressively available,13–18 reinforcing the evi-
dence for their effectiveness and safety out with the setting of ran-
domized clinical trials.19 Thus, we could foresee that the proportion
of patients treated with NOACs will progressively increase among
European patients, and data from the EORP-AF Long-Term Registry
will provide further insights into NOAC use in European countries.
Persistence with OAC therapy, particularly related to NOACs, is
of pivotal importance in preventing thromboembolism.20–23 Also,
appropriate OAC prescription according to thromboembolic risk
strata is central in reducing the occurrence of both thromboembolic
events and death among AF patients. Data from EORP-AF 1-year
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Cox Regression analysis for clinical factors
associated with death occurrence by 2-year follow-up
Hazard
ratio
95% confidence
interval
P-value
Age (per year) 1.06 1.04–1.07 ,0.0001
Other main reason for
admission vs. AF
2.01 1.48–2.75 ,0.0001
First detected AF vs.
permanent AF
1.83 1.30–2.57 0.0005
None vs. regular physical
activity
2.88 1.67–4.96 0.0001
Chronic heart failure 2.25 1.63–3.11 ,0.0001
Chronic kidney disease 2.23 1.68–2.95 ,0.0001
Diabetes 1.66 1.26–2.19 0.0003
Malignancy 1.56 1.01–2.39 0.0430
Heparin 1.60 1.04–2.47 0.0327
Statins 0.68 0.52–0.89 0.0053
Calcium-channel
blockers
0.46 0.26–0.79 0.0050
ACE inhibitors 0.66 0.25–0.87 0.0032
ACE, angiotensin-converting enzyme; AF, atrial fibrillation.
Stroke/TIA/peripheral embolism and/or Mortality
odds ratio and 95% wald CL
Mortality - Cox model
Hazard ratio and 95% likelihood CL
Malignancy
A
B
No physical activity vs. intensety
Diabetes mellitus
Chronic kidney discase
Chronic heart failure
Other vs. Atrial fibrillation as primary reason
First detected vs. persistent
Age
Malignancy
Minor bleeding
No physical activity vs. intensety
Diabetes mellitus
Restrictive cardiomyopathy
Chronic kidney discase
Chronic heart failure
Other vs. Atrial fibrillation as primary reason
First detected vs. persistent
Age
0.1 1 10
Odds ratio
0.1 1 10
Hazard ratio
Figure 5 Forest plots for multivariate predictors of composite outcome and all-cause death. (A) Stroke/transient ischaemic attack/peripheral
embolism and/or mortality. (B) All-cause mortality.
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follow-up analysis found that ESC guideline-adherent treatment was
associated with significantly better outcomes.6 Specifically, inappro-
priately prescribed OAC therapy is associated with a higher risk for
the composite outcome of ‘all-cause death and any TE’, with under-
treatment or overtreatment conferring a 60% excess relative risk
for this composite outcome.
Our data emphasize the high risk of mortality and hospitalizations
of AF patients over a long-term follow-up, consistent with the
1-year follow-up data7 and other previous reports.24 Different
from the previous follow-up report, AF per se does not seem to
be the main determinant of death. Moreover, the association
between the use of calcium-channel blockers, ACE inhibitors, and
statins and the lower mortality, as well as the different co-morbid
conditions as predictors of increased mortality, seems to suggest
how the overall clinical status (and appropriate treatments) would
be the major factor in determining mortality risk among AF patients,
perhaps beyond what would be expected from stroke risk strata and
OAC therapy use.
Together with recent observations about the higher risk for car-
diovascular events associated with the presence of polypharmacy
(defined as the contemporary use of five or more drugs) and the
poorer clinical status of such patients,25 these data suggest the
need for additional steps towards a more comprehensive clinical
evaluation and medical management of AF patients to reduce mor-
tality, going beyond stroke risk assessment and OAC prescription.
Limitations
Themost important limitation of our study is its observational nature,
and given its modest size, it was not powered to detect differences in
some endpoints. Moreover, our study is based on cardiologist-
managed patients. Another major limitation is the high number of
patients lost to follow-up that may hamper the discriminatory ability
of some analyses, potentially reducing generalizability of the results.
Finally, data on anticoagulation control are not currently available
for this cohort and cannot be considered in this analysis.
Conclusions
In this 2-year follow-up report from EORP-AF, mortality rates with
AF are still high (particularly from cardiovascular causes), despite
the high prevalent use of OAC. Improved management strategies
to reduce major adverse outcomes in AF patients are needed.
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